Forward Looking Statement and Non-GAAP Disclaimer This document has been prepared by Colfax Corporation, a Delaware corporation ("Colfax"), solely for informational purposes. Upon completion of the intended separation of

March 14, 2022 Investor Presentation

Enovis: An Innovation Driven Medical Technology Company Exhibit 99.1

Forward Looking Statement and Non-GAAP

Disclaimer This document has been prepared by Colfax Corporation, a Delaware corporation ("Colfax"), solely for informational purposes. Upon completion of the intended separation of Colfax's fabrication technology and specialty

medical technology businesses (the "Separation"), Colfax will retain the specialty medical technology business and will change its name to Enovis Corporation (the "Company" or "Enovis"). References herein to the

terms "Colfax" and "Enovis," when used in a historical context, refer to Colfax and its consolidated subsidiaries before giving effect to the Separation and, when used in the future tense, refer to Enovis and its consolidated

subsidiaries after giving effect to the Separation. Forward-Looking Statements This document includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of

1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis's plans, goals, objectives, outlook, expectations and intentions, including the Separation, and the timing, method and anticipated benefits of

the Separation and other statements that are not historical or current fact. Forward-looking statements are based on Enovis's current expectations and involve risks and uncertainties that could cause actual results to differ materially from

those expressed or implied in such forward-looking statements, including general risks and uncertainties such as market conditions, economic conditions, geopolitical events, changes in laws, regulations or accounting rules, fluctuations in interest

rates, terrorism, wars or conflicts, major health concerns, natural disasters or other disruptions of expected business conditions. Factors that could cause Enovis's results to differ materially from current expectations include, but are not

limited to, risks related to the impact of the COVID-19 global pandemic, including the rise, prevalence and severity of variants of the virus, actions by governments, businesses and individuals in response to the situation, such as the scope and

duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response; material delays and cancellations of medical procedures; supply chain disruptions; the impact on creditworthiness and

financial viability of customers; macroeconomic conditions; the war in the Ukraine and escalating geopolitical tensions as a result of Russia's invasion of the Ukraine; risks relating to the Separation, including the final approval of the

Separation by Colfax's board of directors, the uncertainty of obtaining regulatory approvals, Colfax's ability to satisfactorily complete steps necessary for the Separation and related transactions to be generally tax-free for U.S.

federal income tax purposes, the ability to satisfy the necessary conditions to complete the Separation on a timely basis, or at all, the ability to realize the anticipated benefits of the Separation, developments related to the impact of the

COVID-19 pandemic on the Separation, and the financial and operating performance of Enovis following the Separation; other impacts on Enovis's business and ability to execute business continuity plans; and the other factors detailed in

Colfax's reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K as well as the other risks discussed in Colfax's filings with the SEC. In addition,

these statements are based on assumptions that are subject to change. This document speaks only as of the date hereof. Enovis disclaims any duty to update the information herein. Non-GAAP Financial Measures This document includes a

presentation of adjusted EBITDA and adjusted EBITDA Margin and other financial measures that are not calculated in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"), which Enovis uses

to measure the performance of its business. Adjusted EBITDA represents net income (loss) from continuing operations excluding the effect of restructuring and other related charges, European Union Medical Device Regulation ("MDR")

and related costs, acquisition-related intangible asset amortization and other non-cash charges, intangible asset impairment charges, strategic transaction costs, pension settlement gains and losses, and debt extinguishment charges, as well as

interest expense net, income tax expense (benefit), and depreciation and other amortization. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA. Further, Enovis presents adjusted EBITDA (and adjusted

EBITDA margin) on a segmented and organic/core basis, which is subject to the same adjustments as adjusted EBITDA. Lastly, Enovis presents pro forma adjusted EBITDA which includes the same adjustments above, excludes stock compensation expense, and

reflects corporate cost in all periods presented. Organic or core sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations. The non-GAAP financial measures provided herein are adjusted for certain

items as presented in the Appendix and should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measures, and may not be comparable to similarly titled measures reported by other companies. Management

believes that these non-GAAP financial measures provide useful information to investors by offering additional ways of viewing Enovis's results. Management also believes that presenting these measures allows investors to view its performance

using the same measures that Enovis uses in evaluating our financial and business performance and trends. A reconciliation of adjusted EBITDA and adjusted EBITDA Margin to the closest GAAP financial measure is not available without unreasonable

efforts on a forward-looking basis due to the impact and timing on future operating results arising from items excluded from these measures. No Solicitation, No Offer, Additional Information This communication shall not constitute an offer of

any securities for sale, nor shall there be any offer, safe or distribution of securities in any jurisdiction in which such offer, sale or distribution would be unlawful prior to appropriate registration or qualification under the securities law of

such jurisdiction. For additional information with respect to Colfax and Enovis, please refer to Colfax's filings with the SEC, and with respect to the Separation, please refer to the registration statement on Form 10 of ESAB Corporation, as

it may be further amended, on file with the SEC ("Form 10"). The consummation of the Separation is subject to customary conditions, as further described in the Form 10. The financial information included in this document may not

necessarily reflect Enovis's financial position, results of operations, and cash flows in the future or what Enovis's financial position results of operations, and cash flows would have been had Enovis been a standalone independent,

publicly traded company during the periods presented. Certain Definitions As used in this document, references to "DD" mean "double digit," references to "LDD" mean "low double digit," references

to "HSD" mean "high single-digit" and references to "MSD" mean "mid-single digit."

Matt Trerotola CEO Brady Shirley

President & COO Chris Hix EVP & CFO Presenters Today

Foundation in attractive orthopedic

market with room for expansion Experienced leadership team leveraging proven business system Clear strategy and momentum for HSD organic growth fueled by innovation Significant margin improvement path through mix, productivity, and scale Many

acquisition vectors and ample capital to accelerate growth and compound value MedTech Growth Company Positioned for Significant Value Creation

Introduction to Enovis

Enovis is a medical technology

company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, extraordinary talent and innovation, we create

better together' by partnering with healthcare professionals. Our extensive range of products, services and integrated technologies fuel active lifestyles. #CreatingBetterTogether Who is Enovis?

Strong Global Positions in Attractive

Segments PF sales for full-year revenue contribution from Mathys, Trilliant, and MedShape acquisitions. PF aEBITDA for full-year aEBITDA contribution from Mathys, Trilliant and MedShape and 2021 legacy Colfax corporate costs allocated to Enovis on

an on-going basis . Refer to Appendix for non-GAAP reconciliations. Positioned for significant growth and value creation Two Attractive Business Segments 2021 Performance Fast growing reconstructive platform DJO Surgical DD growth engine in US,

leading in Shoulder and rapid adoption in Knee & Hip Globalized footprint and offering through acquisition of Mathys Expansion into attractive Foot & Ankle market in 2021 Global leader in prevention & recovery (P&R) Global leader in

rigid bracing and soft goods Reshaping care path with MotionMD and MotioniQ digital solutions Technology leader in recovery sciences with broad offering in advanced rehabilitation modalities $216mm PF aEBITDA2 $1,516mm PF Sales1

Source: Orthoworld 2021 Orthopedic

Industry Annual Report, public company filings, Wall Street research, Forbes. Surgical Implants and Instrumentation Prevention & Rehabilitation (P&R) Market CAGR 3-4% 7-8% 3-4% 6-7% 2-3% ~4% 9 8 3 7 10 6 5 Trauma Spine Our Recon served

markets $B $48B Enovis competes in half of the $53B Orthopedics market and "touches" nearly all Market Growth Trends Provide Runway Enovis is well-positioned in segments with strong long-term growth drivers 3-4% Aging but active

population, rising obesity Transitioning to outpatient care Innovation improving the quality of care Our P&R served markets Addressing Large, Attractive Ortho Market

PREVENTION Off-loading braces Back

braces Cold therapy SURGICAL Shoulders Knees Hips Foot/Ankle RECOVERY Post-op braces Walker boots Cold therapy PERFORMANCE Athletic braces Muscle stimulation REHAB Electrotherapy Laser therapy Heat/cold therapy Traction devices PREVENTION REPAIR

RECOVERY Brand leverage with hospitals, surgeons, clinicians, patients Digital workflow solutions for clinics Connected medicine solutions for patient journey Full "episode of care" partner to ambulatory surgery centers (ASC) STRATEGIC

ADVANTAGES Leveraging broad and deep market access and technology for strategic advantage Uniquely Positioned Across Full Ortho Care Continuum

Source: Orthoworld 2021 Orthopedic

Industry Annual Report, public company filings, Wall Street research, Forbes. 2021 revenue, as reported. Enovis is positioned for share gain, scale, and expansion Competitive Ortho Landscape Big, broad majors Scaled, differentiated players Focused

innovators Big enough for healthy margins but additional room to scale Small enough to operate like an innovator Can select most valuable growth paths Ample bolt-on opportunities, attractive path to market/scale for innovators ~30 players in

$0.1-0.5B range >$3B $0.5 - $3B <$0.5B ~1,000 pre-revenue or early revenue players Enovis' Attractive Position Ortho Revenue1 Scaled and Agile in Fragmented Industry

~20% aEBITDA Margin $2B+ Annual

Sales HSD Organic Revenue Growth Strategic Opportunities 3-Year Goals Compounding value creation from growth, margins, and investment Shaping P&R platform for sustained MSD growth Rapidly expanding high-margin, DD growth Recon

platform Expanding margins with a clear strategy and EGX Accelerating growth through technology investments and acquisitions Clear Strategy for Shareholder Value Creation

See Appendix for reconciliation of

pro forma sales. Enovis Sales Performance & Goals Improve and shape P&R Aggressively grow and expand Recon Enter adjacent high-growth segments Extend P&R leadership Scale Recon 1 Clear path to $2B and beyond with HSD organic growth and

expanded margin profile Realizing Our Vision - High-Value MedTech Growth Company

Joining Board upon consummation of

separation. Mitch Rales Matt Trerotola Brady Shirley1 Barbara Bodem1 Liam Kelly Angie Lalor1 Phil Okala Christine Ortiz1 Clay Perfall Rajiv Vinnakota Sharon Wienbar Chairman, Colfax, Danaher Co-Founder CEO President & COO Former SVP & CFO of

Hillrom CEO of Teleflex Incorporated Former SVP of HR, Danaher, 3M COO, UPenn Health Systems Prof. of Materials Sciences and Engineering, MIT Operating Executive, Tailwind Capital President, Institute for Citizens & Scholars Former Partner,

Scale Venture Partners Board of Directors Enovis Senior Leadership Team Matt Trerotola CEO Chris Hix EVP & CFO Brad Tandy General Counsel Dan Pryor EVP BD, Strategy Patty Lang CHRO Brady Shirley President & COO Senior leaders with over 80

years of combined MedTech experience Strong Leadership Team, Deep MedTech Experience

EGX supporting growth acceleration

and margin improvement Our Enovis Growth eXcellence business system is a set of tools, processes, and culture, incorporating continuous improvement to drive and fuel growth Drive Growth Fuel Growth Talent and Culture Our Proven, Powerful Business

Enovis commitment to developing our

talent fuels our success Actionable annual engagement survey with 90%+ participation and overall scores in top quartile Enterprise-wide focus on diversity and inclusion Powerful combination of DJO & Colfax High performance culture 63% increase

in training and development programs Virtual operations boot camp in 2020 Teachable, repeatable EGX tools and processes We enable great patient outcomes The best team wins Innovation defines our future We deliver outstanding results the right way is

our way of life Continuous improvement Creating Better Together Attract the Best Talent Develop Internal Talent Pipeline Retain Thru Engagement, Inclusion & Opportunity Harnessing the Power of Our Talent with Purpose, Values,

Note: Refer to Appendix for non-GAAP

reconciliations. Enovis EGX journey has strong momentum using tools that had big impact at ESAB Above Market Organic Growth Productivity Foundation For Further Margin Expansion Lean Supply Chain: Safety, Delivery, Productivity Agile Growth:

Innovation cadence, Commercial excellence Scalable Support: Shared services, Streamline, Automate Safety, Delivery, Productivity Innov. cadence, Commercial excellence Insource, Streamline Lean Supply Chain: Agile Growth: Scalable Support: CBS/EGX

Improvement Journeys 2015 2016 2017 2018 2019 2020 2021 13.8% 17.9% aEBITDA Margin Improvement $2.0B $2.4B Revenue Growth Business System Proven to Drive Significant Long-Term Value

See Appendix for reconciliation of

sales pro forma for full-year revenue contribution from Mathys, Trilliant, and MedShape. 2018 2021 Recon P&R $1.5B $1.2B Ortho Market Growth Scaling top line growth and outperforming the market in Recon and P&R Recon P&R Operational

improvements Investments in DD recon engine Innovation cadence High growth acquisitions Above market in Recon and P&R Above market in Recon 1 Enovis Evolution to HSD Organic Growth Underway

Note: Current revenue contribution

is pro-forma for full-year revenue contribution from Mathys, Trilliant, and MedShape. Current Revenue Contribution 2022+ Expected Revenue Growth Recon 32% @ 10 - 15% P&R 68% @ 4 - 5% MSD+ HSD Organic Revenue Growth Demonstrated DD recon

growth and P&R at/above market expected to drive us to HSD On Track for HSD Organic Growth

Focused Growth Strategies

Focused Growth Strategies Rapidly

expanding high-margin, DD growth Recon platform Tremendous opportunities to drive strong and profitable growth Shaping P&R platform for sustained MSD growth Globalizing and expanding recon platform Expanding margins with a clear strategy and EGX

Accelerating growth through technology investments and acquisitions 1 2C 3 4 Building Foot & Ankle business with near-term pathway to $100mm+ 2B Extending US Surgical DD growth engine 2A

Focused Growth Strategies Shaping

P&R platform for sustained MSD growth Globalizing and expanding recon platform Expanding margins with a clear strategy and EGX Accelerating growth through technology investments and acquisitions 1 2C 3 4 Building Foot & Ankle business with

near-term pathway to $100mm+ 2B Extending US Surgical DD growth engine 2A Rapidly expanding high-margin, DD growth Recon platform

Market Leader in Prevention &

Recovery with Differentiated Brands Source: Based on internal Enovis analysis. P&R Sales & Market Position1 Market Leadership Technology and Brand Leadership $5B market expected to grow 3-4% per year Industry-defining products across

Orthopedics Leader in fast growing Sports Medicine segment MotionMD workflow software solution drives 45% of US Clinics Leader in therapy modalities strengthened by LiteCure Strong International Position: 32% ex-US Sales Aircast

EXOS Chattanooga LiteCure DonJoy Recovery Sciences ~$1.0B #1 Globally in Bracing #1 Globally in Rehab #2 In Bone Stimulation Attractive leading global positions in bracing and recovery sciences Industry Leadership

Prevention and Recovery Markets with